WallStreetZenWallStreetZen

NASDAQ: CLLS
Cellectis Sa Stock

Open Broker Account
$2.21-0.03 (-1.34%)
Updated Dec 9, 2022
CLLS Price
$2.21
Fair Value Price
$4.82
Market Cap
$100.70M
52 Week Low
$2.00
52 Week High
$9.30
P/E
-0.96x
P/B
0.74x
P/S
4.7x
PEG
N/A
Dividend Yield
N/A
Revenue
$22.18M
Earnings
-$104.32M
Gross Margin
85%
Operating Margin
-470.32%
Profit Margin
-470.3%
Debt to Equity
0.98
Operating Cash Flow
-$107M
Beta
1.33
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

CLLS Overview

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Zen Score

Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CLLS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CLLS ($2.21) is undervalued by 54.18% relative to our estimate of its Fair Value price of $4.82 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CLLS ($2.21) is significantly undervalued by 54.18% relative to our estimate of its Fair Value price of $4.82 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CLLS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CLLS due diligence checks available for Premium users.

Be the first to know about important CLLS news, forecast changes, insider trades & much more!

CLLS News

Valuation

CLLS fair value

Fair Value of CLLS stock based on Discounted Cash Flow (DCF)
Price
$2.21
Fair Value
$4.82
Undervalued by
54.18%
CLLS ($2.21) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CLLS ($2.21) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CLLS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CLLS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.96x
Industry
13.17x
Market
21.21x

CLLS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.74x
Industry
4.91x
CLLS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CLLS's financial health

Profit margin

Revenue
$1.9M
Net Income
-$28.5M
Profit Margin
-1,481.9%
CLLS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CLLS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$279.6M
Liabilities
$134.0M
Debt to equity
0.98
CLLS's short-term assets ($140.27M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CLLS's short-term assets ($140.27M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CLLS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CLLS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$26.0M
Investing
-$61.0k
Financing
-$4.1M
CLLS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CLLS vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CLLS$100.70M-1.34%-0.96x0.74x
GNTA$101.10M-3.81%-25.69x2.79x
ALZN$101.21M-0.93%-7.07x9.05x
KRON$100.14M+2.33%-0.60x0.37x
IFRX$102.11M-1.70%-2.93x1.02x

Cellectis Sa Stock FAQ

What is Cellectis Sa's quote symbol?

NASDAQ: CLLS) Cellectis Sa trades on the NASDAQ under the ticker symbol CLLS. Cellectis Sa stock quotes can also be displayed as NASDAQ: CLLS.

If you're new to stock investing, here's how to buy Cellectis Sa stock.

What is the 52 week high and low for Cellectis Sa (NASDAQ: CLLS)?

(NASDAQ: CLLS) Cellectis Sa's 52-week high was $9.30, and its 52-week low was $2.00. It is currently -76.24% from its 52-week high and 10.5% from its 52-week low.

How much is Cellectis Sa stock worth today?

(NASDAQ: CLLS) Cellectis Sa currently has 45,565,810 outstanding shares. With Cellectis Sa stock trading at $2.21 per share, the total value of Cellectis Sa stock (market capitalization) is $100.70M.

Cellectis Sa stock was originally listed at a price of $39.30 in Mar 25, 2015. If you had invested in Cellectis Sa stock at $39.30, your return over the last 7 years would have been -94.38%, for an annualized return of -33.71% (not including any dividends or dividend reinvestments).

How much is Cellectis Sa's stock price per share?

(NASDAQ: CLLS) Cellectis Sa stock price per share is $2.21 today (as of Dec 9, 2022).

What is Cellectis Sa's Market Cap?

(NASDAQ: CLLS) Cellectis Sa's market cap is $100.70M, as of Dec 10, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Cellectis Sa's market cap is calculated by multiplying CLLS's current stock price of $2.21 by CLLS's total outstanding shares of 45,565,810.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.